Evidence map›Paper›PMID 30717671›Full record

ArticleBMC medical research methodology2019

Challenges and benefits of integrating diverse sampling strategies in the observation of cardiovascular risk factors (ORISCAV-LUX 2) study.

Ala'a Alkerwi, Jessica Pastore, Nicolas Sauvageot, Gwenaëlle Le Coroller, Valéry Bocquet, Marylène d'Incau, Gloria Aguayo, Brice Appenzeller, Dritan Bejko, Torsten Bohn and 8 more

Abstract read
In one paragraph

Article in BMC medical research methodology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Comparing national device-based physical activity surveillance systems: a systematic review.The international journal of behavioral nutrition and physical activity · 2024
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ala'a AlkerwiLuxembourg Institute of Health (LIH), Department of Population Health, 1A rue Thomas Edison, L-1445, Strassen, Luxembourg. alaa.alkerwi@lih.lu.ORCID 0000-0002-7448-3936
Jessica PastoreLuxembourg Institute of Health (LIH), Department of Population Health, 1A rue Thomas Edison, L-1445, Strassen, Luxembourg.
Nicolas SauvageotLuxembourg Institute of Health (LIH), Department of Population Health, 1A rue Thomas Edison, L-1445, Strassen, Luxembourg.
Gwenaëlle Le CorollerLuxembourg Institute of Health (LIH), Department of Population Health, 1A rue Thomas Edison, L-1445, Strassen, Luxembourg.
Valéry BocquetLuxembourg Institute of Health (LIH), Department of Population Health, 1A rue Thomas Edison, L-1445, Strassen, Luxembourg.
Marylène d'IncauLuxembourg Institute of Health (LIH), Department of Population Health, 1A rue Thomas Edison, L-1445, Strassen, Luxembourg.
Gloria AguayoLuxembourg Institute of Health (LIH), Department of Population Health, 1A rue Thomas Edison, L-1445, Strassen, Luxembourg.
Brice AppenzellerLuxembourg Institute of Health (LIH), Department of Population Health, 1A rue Thomas Edison, L-1445, Strassen, Luxembourg.
Dritan BejkoLuxembourg Institute of Health (LIH), Department of Population Health, 1A rue Thomas Edison, L-1445, Strassen, Luxembourg.
Torsten BohnLuxembourg Institute of Health (LIH), Department of Population Health, 1A rue Thomas Edison, L-1445, Strassen, Luxembourg.
Laurent MalisouxLuxembourg Institute of Health (LIH), Department of Population Health, 1A rue Thomas Edison, L-1445, Strassen, Luxembourg.
Sophie CouffignalLuxembourg Institute of Health (LIH), Department of Population Health, 1A rue Thomas Edison, L-1445, Strassen, Luxembourg.
Stephanie NoppeCentre Hospitalier du Luxembourg (CHL), Luxembourg City, Luxembourg.
Charles DelagardelleCentre Hospitalier du Luxembourg (CHL), Luxembourg City, Luxembourg.
Jean BeisselCentre Hospitalier du Luxembourg (CHL), Luxembourg City, Luxembourg.
Anna ChiotiMinistry of Health, Directorate of Health, Luxembourg City, Luxembourg.
Saverio StrangesLuxembourg Institute of Health (LIH), Department of Population Health, 1A rue Thomas Edison, L-1445, Strassen, Luxembourg.
Jean-Claude SchmitMinistry of Health, Directorate of Health, Luxembourg City, Luxembourg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt is challenging to manage data collection as planned and creation of opportunities to adapt during the course of enrolment may be needed. This paper aims to summarize the different sampling strategies adopted in the second wave of Observation of Cardiovascular Risk Factors (ORISCAV-LUX, 2016-17), with a focus on population coverage and sample representativeness.

methodsData from the first nationwide cross-sectional, population-based ORISCAV-LUX survey, 2007-08 and from the newly complementary sample recruited via different pathways, nine years later were analysed. First, we compare the socio-demographic characteristics and health profiles between baseline participants and non-participants to the second wave. Then, we describe the distribution of subjects across different strategy-specific samples and performed a comparison of the overall ORISCAV-LUX2 sample to the national population according to stratification criteria.

resultsFor the baseline sample (1209 subjects), the participants (660) were younger than the non-participants (549), with a significant difference in average ages (44 vs 45.8 years; P = 0.019). There was a significant difference in terms of education level (P < 0.0001), 218 (33%) participants having university qualification vs. 95 (18%) non-participants. The participants seemed having better health perception (p < 0.0001); 455 (70.3%) self-reported good or very good health perception compared to 312 (58.2%) non-participants. The prevalence of obesity (P < 0.0001), hypertension (P < 0.0001), diabetes (P = 0.007), and mean values of related biomarkers were significantly higher among the non-participants. The overall sample (1558 participants) was mainly composed of randomly selected subjects, including 660 from the baseline sample and 455 from other health examination survey sample and 269 from civil registry sample (constituting in total 88.8%), against only 174 volunteers (11.2%), with significantly different characteristics and health status. The ORISCAV-LUX2 sample was representative of national population for geographical district, but not for sex and age; the younger (25-34 years) and older (65-79 years) being underrepresented, whereas middle-aged adults being over-represented, with significant sex-specific difference (p < 0.0001).

conclusionThis study represents a careful first-stage analysis of the ORISCAV-LUX2 sample, based on available information on participants and non-participants. The ORISCAV-LUX datasets represents a relevant tool for epidemiological research and a basis for health monitoring and evidence-based prevention of cardiometabolic risk in Luxembourg.

Indexed as

Patient SelectionAdultCardiovascular DiseasesCross-Sectional StudiesFemaleHealth SurveysHumansLuxembourgMaleMiddle AgedPatient ParticipationPrevalenceRisk FactorsEpidemiologyFollow-up studies, population healthPopulation-based studySample representativeness

Identifiers

PMID30717671
PMCPMC6360765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.